Wed, Jan. 14, 11:51 AM
- Flamel Technologies (FLML -25%) drops on a 6x surge in volume in apparent response a favorable ruling from the USPTO for Jazz Pharmaceuticals (JAZZ +3.1%) and against the petitions from Par Pharmaceuticals, Roxane Labs and Amneal Pharmaceuticals. The decision reaffirmed the validity of four patents related to Xyrem (#'s 7,895,059, 8,457,988, 7,668,730, 8,589,182).
- In October, Canaccord Genuity analyst John Newman published a research report reiterating his Buy recommendation on Jazz Pharmaceuticals (JAZZ +3.8%) with a $163 price target based on his view that Flamel's NDA for its once-daily version of Xyrem (sodium oxybate), to be filed under the 505(NYSE:B)(2) paragraph IV pathway, will reference Jazz's orange book-listed patents. This will trigger a lawsuit and and an automatic 30-month stay of approval.
- The delay will give Jazz more time to develop its once-daily version, JZP-386, which should enter Phase 2 this year.
Apr. 22, 2013, 11:02 AMBarnes Group (B -2%) says it's completed the sale of its North American distribution business to MSC Industrial Direct (MSM +0.5%), for approximately $550M in cash. As a result of the sale, B has updated FY13 guidance, saying that it will report the sold unit as discontinued operations beginning with Q1. It now expects FY13 revenue from continuing operations to grow 17% to 20% Y/Y. GAAP EPS are now anticipated to be in the range of $1.71 to $1.86. | Comment!
Feb. 22, 2013, 12:53 PM
Aug. 29, 2011, 2:01 PM
B vs. ETF Alternatives
Barnes Group Inc is an industrial and aerospace manufacturer and service provider, serving end markets and customers. Its engineered products and services are used in critical applications that provide transportation, manufacturing and technology.
Other News & PR